Managing regulatory information in the pharmaceutical industry is challenging in post-pandemic Europe. The introduction of new requirements surrounding substances, products, organizations, and referential (SPOR) data and a new shared target operating model (TOM) across Industry and regulators are forcing companies to rethink their approach to managing regulatory information and submissions. This is driving new data management initiatives to align existing regulatory data with master data systems, streamline data submissions, and improve data maintenance capabilities, according to Jens-Olaf Vanggaard, senior director, Global Safety, Regulatory & Quality Solutions, IQVIA.